Rapamycin is
not a new subject in this blog, but it did reappear in the recent Yale paper
about what drugs “should” help in some autism. One of our Chinese readers did
trial it years ago, based on a published case history from China. Some readers of Epiphany ASD have children with TSC and receive
everolimus, a close relative of rapamycin. Everolimus is prescribed by
specialist physicians for approved indications associated with TSC. Other
parents have trialed rapamycin more recently.
For more
than a decade, researchers have reported that the drug rapamycin can improve
autism-like behaviours in animal models. At first glance, the latest study from
UCLA appears to be just another example. Adult mice exposed to inflammation
before birth received a single dose of rapamycin, and within two hours many of
their autism-like features—including sensory hypersensitivity, repetitive
behaviours, neuronal hyperexcitability and abnormal brain network activity—were
dramatically improved.
https://www.uclahealth.org/news/release/drug-reverses-autism-like-brain-changes-adult-mice-within
It would be
easy to conclude that this is simply another story about a promising drug.
I think that
would miss the real significance of the work.
The UCLA
study is not really about rapamycin.
It is about what
rapamycin has taught us about the autistic brain.
For decades
autism has been viewed primarily as a disorder of abnormal brain development.
If neural circuits develop incorrectly before birth, the assumption has been
that they cannot later be corrected. Treatment therefore focused on helping
individuals adapt to those differences rather than attempting to restore the
function of the underlying circuits.
The UCLA
study challenges that assumption.
The
remarkable finding was not simply that rapamycin improved behaviour.
It was how
quickly the improvements occurred.
Within
approximately two hours, neurons that had been firing excessively returned
towards normal activity. Functional communication between brain regions
improved. Sensory over-responsivity diminished. Repetitive behaviours became
less pronounced.
Two hours is
far too short for the brain to rebuild abnormal neural connections that
developed before birth.
Instead, the
study suggests something much more exciting:
Even when
abnormal brain anatomy remains, the function of those circuits may still be
remarkably modifiable in adulthood.
That is a
profound change in thinking.
The
implications extend far beyond rapamycin itself.
They suggest
that future autism therapies may not need to "repair" the autistic
brain. Instead, they may simply need to restore healthier patterns of neuronal
activity.
If this
principle also proves true in humans, it could fundamentally change how autism
is treated.
Five
take-home messages
Before
exploring the details, here are the five ideas that I believe make the UCLA
study important.
1. Adult
autistic brain circuits remain surprisingly plastic
The study
demonstrates that functional improvements can occur rapidly, even when
structural developmental abnormalities remain unchanged.
2.
Different causes of autism may converge on common biological pathways
Genetic
disorders such as tuberous sclerosis, environmental models such as prenatal
valproic acid exposure, and maternal immune activation all appear capable of
producing excessive neuronal activity through related signalling pathways
involving mTOR.
3.
Rapamycin is probably not the future treatment
Its greatest
contribution may be demonstrating that adult brain circuits can still be
rebalanced.
4.
Precision medicine is replacing one-size-fits-all autism treatment
Rather than
treating "autism," future therapies are likely to target the specific
biological pathway that is abnormal in each individual.
5. Autism
clinical trials may need redesigning
If some
therapies produce meaningful physiological improvements within hours or days,
measuring outcomes only after three months may miss important information about
how they actually work.
A
timeline of how our understanding has evolved
The UCLA
study did not appear in isolation.
It
represents the latest step in a scientific journey that has gradually
transformed our understanding of autism biology over the past fifteen years.
Table 1. How our understanding of rapamycin and autism has evolved
|
Year
|
Discovery
|
Major Insight
|
|
2012
|
Rapamycin improves autistic-like behaviour in adult mouse models of tuberous sclerosis (TSC).
|
Excessive mTOR signalling can directly contribute to autistic behaviours, establishing mTOR as a potential therapeutic target.
|
|
2019
|
Rapamycin improves social interaction in mice exposed prenatally to valproic acid (VPA).
|
mTOR dysregulation is not confined to rare genetic disorders and may contribute to some forms of non-syndromic autism.
|
|
2022
|
Italian researchers demonstrate that rapamycin restores neuronal excitability without correcting the original potassium channel defect.
|
Behaviour can improve through rapid functional normalization of neuronal circuits rather than structural repair of the developing brain.
|
|
2026
|
UCLA researchers show that a single dose of rapamycin rapidly normalizes neuronal activity, sensory processing and functional brain networks within approximately two hours.
|
Adult autistic brain circuits remain functionally modifiable even after abnormal development, shifting the focus from structural repair to physiological rebalancing.
|
|
Future
|
Precision medicine identifies the disrupted biological pathway in each individual rather than treating autism as a single disorder.
|
The goal becomes restoring healthy physiology rather than simply suppressing symptoms, using individualized combinations of targeted therapies.
|
Viewed
together, these studies reveal a gradual evolution in scientific thinking.
Originally,
researchers hoped rapamycin might become a treatment for tuberous sclerosis.
Today, it
appears to have served an even more important purpose.
It has
become the experimental tool that demonstrated a fundamental principle:
Adult
autistic brain circuits remain remarkably plastic.
How the
story began
The
rapamycin story started with tuberous sclerosis complex (TSC).
TSC is
caused by mutations in either the TSC1 or TSC2 genes. These genes normally act
as brakes on the mTOR signalling pathway. When they are defective, mTOR becomes
chronically overactive, resulting in abnormal cell growth, epilepsy, benign
tumours and a high incidence of autism.
Rapamycin
was therefore an obvious therapeutic candidate because it directly inhibits
mTOR.
Remarkably,
adult mouse models of TSC showed substantial improvements in social behaviour
following treatment.
This
immediately raised an intriguing question.
Was
rapamycin correcting something unique to tuberous sclerosis?
Or had
researchers stumbled upon a biological pathway that might also contribute to
other forms of autism?
That
question led to the next important discovery.
In 2019,
Japanese researchers investigated the prenatal valproic acid (VPA) model, one
of the best-established environmental models of autism.
Valproic
acid exposure during pregnancy has long been known to increase the risk of
autism in humans. In mice, prenatal exposure produces many autism-like features
including altered social interaction, repetitive behaviours and abnormal
neuronal development.
The
researchers found that rapamycin again improved behaviour while simultaneously
reducing excessive activation of the mTOR pathway.
This
suggested that mTOR dysregulation might not be restricted to rare genetic
syndromes.
Instead,
very different causes of autism might converge on the same downstream
biological pathway.
The next
breakthrough came in 2022.
An Italian
research group studied neurons within the nucleus accumbens, a brain region
involved in motivation, reward and social behaviour.
They
discovered that rapamycin rapidly restored normal firing patterns in
hyperexcitable neurons and improved social behaviour.
Perhaps the
most surprising observation was what did not happen.
The
underlying potassium channel abnormality remained.
Neuronal
structure remained largely unchanged.
Rapamycin
had restored neuronal function without correcting the original developmental
abnormality.
That finding
hinted that brain circuits might remain physiologically flexible long after
development had finished.
The UCLA
study has now taken that idea much further.
The major
advance is not that rapamycin works
The UCLA
researchers deliberately chose a completely different autism model.
Instead of
using a genetic disorder or prenatal exposure to valproic acid, they exposed
pregnant mice to mild maternal inflammation, mimicking one of the environmental
risk factors associated with autism.
The
offspring later developed many familiar autism-like features:
- sensory over-responsivity
- repetitive behaviours
- neuronal hyperexcitability
- abnormal communication between
brain regions
- increased susceptibility to
seizures
- excessive activation of the mTOR
pathway
Once again,
rapamycin improved nearly every abnormality.
But this
time the researchers looked far more carefully at how quickly those changes
occurred.
The answer
was astonishing.
Within
approximately two hours, neuronal firing patterns, sensory responses and
functional brain connectivity all shifted towards normal.
That is
simply too fast for structural rewiring of the brain.
Instead, the
findings suggest that rapamycin acted primarily by rebalancing the physiology
of existing neuronal circuits.
That
distinction may prove to be one of the most important conceptual advances in
autism research for many years.
It shifts
the question from:
Can we
repair the autistic brain?
to something
much more achievable:
Can we
restore healthier function to autistic brain circuits?
That change
in perspective forms the foundation of modern precision medicine—and it is the
subject of the next section.
Convergence,
Precision Medicine and Why Not Every Autistic Brain Has the Same Biology
One of the
biggest obstacles to developing effective autism treatments has been the
enormous biological diversity hidden behind a single clinical diagnosis.
Two children
may both receive a diagnosis of autism while sharing remarkably few biological
abnormalities.
One may have
a mutation affecting calcium channels.
Another may
have excessive activation of the PI3K-Akt-mTOR pathway.
A third may
have altered GABA signalling.
A fourth may
have neuroimmune dysfunction.
Yet all four
satisfy the diagnostic criteria for autism.
For many
years this heterogeneity has frustrated drug development. Clinical trials often
enrol hundreds of autistic individuals whose underlying biology is completely
different. Even if a treatment works extremely well in one biological subgroup,
the benefit may disappear statistically when averaged across everyone else.
The UCLA
study strengthens an alternative way of thinking.
Instead of
treating autism as one disorder, perhaps we should think of it as many
different disorders that converge on a relatively small number of disturbed
brain circuits.
That concept
lies at the heart of precision medicine.
Different
roads lead to the same destination
One of the
most remarkable observations from the rapamycin literature is that completely
different causes of autism produce surprisingly similar abnormalities.
Consider the
three major animal models discussed so far.
Tuberous
sclerosis
Here the
starting point is genetic.
Mutations in
TSC1 or TSC2 remove the normal brakes on mTOR signalling, producing chronic
overactivation of the pathway.
Prenatal
valproic acid exposure
Here the
initiating event is environmental.
Exposure to
valproic acid during pregnancy alters gene expression during brain development,
ultimately producing abnormal neuronal excitability and excessive mTOR
signalling.
Maternal
immune activation
The UCLA
model begins differently again.
Mild
inflammation during pregnancy alters fetal brain development, eventually
producing neuronal hyperexcitability, sensory dysfunction and abnormal
functional brain networks.
At first
sight these appear to be completely unrelated disorders.
Yet they
converge on remarkably similar downstream abnormalities:
- excessive mTOR signalling
- neuronal hyperexcitability
- disrupted excitation/inhibition
balance
- abnormal functional connectivity
- sensory over-responsivity
- repetitive behaviours
Perhaps even
more strikingly, all three respond to rapamycin.
This pattern
suggests that mTOR may function as a common biological hub where several
apparently unrelated pathways intersect.
That does
not mean mTOR is the cause of autism.
Rather, it
may represent one of the final common pathways through which many different
causes disturb brain function.
The figure
illustrates an important principle.
Most autism
therapies do not directly target mTOR.
Instead,
they influence different parts of a biological network that ultimately
converges on the same endpoint:
normal
neuronal circuit function.
This systems
approach represents a major shift away from searching for a single "autism
gene" or a single "autism drug."
Pitt-Hopkins
syndrome reminds us that biology can move in both directions
Whenever a
new biological pathway becomes fashionable there is a temptation to assume that
every patient has too much or too little of it.
The mTOR
pathway is no exception.
After
reading about tuberous sclerosis and the UCLA study, it would be easy to
conclude that autism is caused by excessive mTOR activity.
That would
be a mistake.
One of the
clearest examples comes from Pitt-Hopkins syndrome.
Pitt-Hopkins
syndrome results from mutations in the TCF4 gene, a transcription factor that
regulates hundreds of genes involved in brain development.
Experimental
studies suggest that reduced TCF4 activity may decrease signalling through the PI3K-Akt-mTOR
pathway, impairing neuronal growth and protein synthesis.
Although
this area is still evolving, the important principle is clear.
If mTOR
signalling is already reduced, further suppressing it with rapamycin could
theoretically worsen the underlying biological abnormality.
The
treatment strategy becomes almost the mirror image of tuberous sclerosis.
Instead of
inhibiting mTOR, researchers have explored ways of restoring trophic
signalling.
These
include:
- IGF-1, which activates the
PI3K-Akt-mTOR pathway.
- Trofinetide, a synthetic analogue of the
IGF-1-derived peptide glypromate (GPE), developed to support synaptic
function.
- BDNF-enhancing approaches, which indirectly support
PI3K-Akt-mTOR signalling and neuronal plasticity.
- Gene therapy, aiming to restore normal TCF4
expression and thereby correct multiple downstream pathways
simultaneously.
The
objective is not to maximise mTOR activity.
Neither is
it to suppress it.
The
objective is to restore normal physiological signalling.
The
Goldilocks principle
The Goldilocks
principle comes from the children's story Goldilocks and the Three Bears, where
Goldilocks rejects porridge that is too hot or too cold, choosing the one that is
just right.
In biology,
the term is used to describe systems that work best within an optimal range.
Too much activity is harmful, but so is too little. The objective is to restore
the system to its normal physiological set point.
Many
signalling pathways operate within an optimal range.
Too much
activity causes disease.
Too little
activity causes disease.
mTOR appears
to behave in exactly this way.
Excessive
activity may produce:
- abnormal protein synthesis
- neuronal hyperexcitability
- impaired autophagy
- abnormal sensory processing
Insufficient
activity may impair:
- dendritic growth
- synapse formation
- neuronal plasticity
- learning and memory
Both
extremes can disturb the development and function of neuronal circuits.
The goal is
therefore not "high mTOR" or "low mTOR."
It is normal
mTOR.
Which
autistic individuals might benefit from mTOR modulation?
This is the
practical question every family eventually asks.
Current
evidence suggests the answer is:
probably
only some of them.
The
strongest rationale currently exists for conditions already known to involve
excessive activation of the PI3K-Akt-mTOR pathway.
Examples
include:
- tuberous sclerosis complex
- PTEN-related syndromes
- PIK3CA-related disorders
- certain forms of macrocephalic
autism
- some individuals with prenatal
valproic acid exposure
- some individuals affected by
maternal immune activation
Other
features may also raise interest, although much more research is needed.
These
include:
- epilepsy
- epileptiform EEG abnormalities
- marked sensory hypersensitivity
- evidence of neuronal
hyperexcitability
Importantly,
none of these features proves that mTOR is abnormal.
They simply
identify groups in which further research may be particularly informative.
Conversely,
disorders such as Pitt-Hopkins syndrome remind us that not every autistic
individual is likely to benefit from mTOR inhibition.
Some may
ultimately require therapies that gently enhance trophic signalling instead.
Precision
medicine replaces one-size-fits-all treatment
This way of
thinking represents one of the biggest changes in autism research.
Historically,
the question was:
Does this
drug treat autism?
Precision
medicine asks a different question.
Does this
drug correct the biological abnormality present in this particular individual?
That may
sound like a subtle distinction.
In reality,
it changes everything.
A future
clinic might begin not by prescribing medication, but by asking:
- Which genes are affected?
- Which signalling pathways are
abnormal?
- Is neuronal excitability
increased or decreased?
- Is mTOR signalling excessive,
insufficient or normal?
- Is neuroinflammation
contributing?
Only then
would treatment be selected.
This is
already common practice in oncology, where cancers are increasingly classified
by their molecular biology rather than by their location in the body.
Autism may
eventually follow a similar path.
A systems
biology approach
One lesson
from the UCLA study is that no single pathway operates in isolation.
The brain
functions as an interconnected network.
Changes in
one signalling pathway inevitably influence many others.
That is why
Figure 2 is so important.
It
illustrates that treatments such as:
- statins,
- metformin,
- pioglitazone,
- IGF-1,
- trofinetide,
- calcium channel blockers,
- bumetanide,
- NAC,
all act at
different points within the network.
Yet many
ultimately converge on the same physiological endpoint:
restoring
healthier neuronal circuit function.
This systems
biology perspective moves us away from asking:
"Which
drug is best?"
towards a
far more useful question:
"Which
combination of interventions is most likely to restore normal physiology in
this individual?"
That
question naturally leads to the next issue.
Even if
rapamycin can rapidly rebalance neuronal circuits, is it actually the right
drug for long-term treatment?
As we shall
see in the next section, the UCLA study itself provides a compelling reason to
think the answer is probably not.
Why
Rapamycin Is Probably Not the Final Answer – Combination Therapy, Clinical
Trials and the Rise of N-of-1 Precision Medicine
At this
point, readers might reasonably ask a simple question.
If rapamycin
can normalize brain function so dramatically in mice, why not simply use
rapamycin to treat autism?
The UCLA
researchers themselves provide the answer.
Ironically,
one of the most important findings in the study was not the initial
improvement.
It was what
happened afterwards.
When
rapamycin was given repeatedly, its effectiveness gradually diminished.
The brain
adapted.
That
observation may ultimately prove just as important as the initial two-hour
response.
The brain
fights back
The nervous
system is remarkably good at maintaining stability.
Neuroscientists
refer to this as homeostasis.
Whenever one
signalling pathway is pushed strongly in one direction, numerous compensatory
mechanisms begin working to restore equilibrium.
This
phenomenon is familiar throughout medicine.
Patients
taking opioids gradually require higher doses to achieve the same effect.
Tolerance
develops to benzodiazepines.
Many
antidepressants require weeks before compensatory changes produce their full
clinical benefit.
Rapamycin
appears to trigger a similar biological response.
Initially,
suppressing excessive mTOR activity restored healthier neuronal function.
With
prolonged treatment, however, compensatory mechanisms gradually reduced its
effectiveness.
The lesson
is important.
It suggests
that completely suppressing one signalling pathway is unlikely to represent the
ideal long-term strategy.
Instead,
future therapies may need to work with the brain's natural homeostatic
mechanisms rather than continually fighting against them.
Rapamycin
may have fulfilled its real purpose
This leads
to what I believe is the central message of the UCLA study.
Rapamycin's
greatest contribution may not be as a treatment. It may be the drug that proved
adult autistic brain circuits can still be rebalanced.
Whether
rapamycin itself ultimately becomes a routine autism therapy is almost
secondary.
The
important discovery is that rapidly restoring normal neuronal physiology
appears possible.
The
challenge now becomes finding safer and more sustainable ways of achieving
exactly the same result.
Could
combination therapy outperform rapamycin?
Modern
medicine has repeatedly discovered that several modest interventions often
outperform one powerful drug.
Hypertension
provides an excellent example.
Doctors
rarely prescribe the maximum dose of a single blood pressure medication.
Instead they
commonly combine two or three lower-dose drugs that act through different
mechanisms.
Blood
pressure is controlled more effectively.
Side effects
are reduced.
Compensatory
physiological responses are minimised.
The same
philosophy may eventually apply to autism.
Instead of
strongly inhibiting one signalling pathway, future treatment may involve gently
nudging several interconnected pathways towards normal physiological function.
No
individual intervention would need to produce a dramatic effect.
Together,
however, they might restore healthy neuronal network activity while avoiding
the biological adaptation observed with chronic rapamycin.
One of the
most useful ways of thinking about autism therapies is to group them according
to where they act within the biological network rather than according to their
traditional medical uses.
Upstream
modulators
These
therapies influence signalling before it reaches mTOR.
Examples
include:
- Statins, which reduce Ras and Rho
signalling through inhibition of protein prenylation.
- Metformin, which activates AMPK,
indirectly reducing excessive mTOR activity.
- Pioglitazone, which reduces inflammatory
signalling while influencing the PI3K-Akt pathway.
- IGF-1, which increases PI3K-Akt
signalling when trophic support is inadequate.
- Trofinetide, which enhances IGF-1-related
neurotrophic signalling.
Direct
mTOR modulators
These drugs
act directly on the pathway itself.
Downstream
modulators
Many
familiar autism interventions act downstream by altering neuronal excitability
rather than directly influencing mTOR.
Examples
include:
- bumetanide
- calcium channel blockers
- memantine
- benzodiazepines
- N-acetylcysteine (NAC)
- neuromodulation
Although
these therapies appear very different pharmacologically, many ultimately
converge on a common physiological objective:
Restoring
healthier neuronal circuit function.
That systems
biology perspective is likely to become increasingly important over the coming
decade.
Do autism
clinical trials need redesigning?
One aspect
of the UCLA study has received surprisingly little attention.
The
improvements occurred within approximately two hours.
That
observation immediately raises an important question.
Are
autism clinical trials measuring outcomes at the right time?
Traditionally,
participants return after several months before researchers assess whether
treatment has been successful.
That makes
perfect sense for therapies expected to produce gradual developmental changes.
It makes
much less sense for therapies that appear to work by rapidly restoring neuronal
physiology.
The UCLA
study suggests that meaningful changes in brain function may occur long before
structural changes become possible.
If so,
waiting three months before making the first assessment may overlook valuable
biological information.
Some
autism interventions appear to act rapidly
Rapamycin is
probably not unique.
Several
interventions have been reported to produce relatively rapid improvements in at
least some autistic individuals.
Examples
include:
- mTOR modulation
- calcium channel blockers in
selected channelopathies
- bumetanide
- N-acetylcysteine (NAC)
- memantine
- benzodiazepines
- corticosteroids in selected
immune-mediated cases
These drugs
have very different pharmacology.
Nevertheless,
many ultimately influence:
- neuronal excitability
- excitation/inhibition balance
- functional brain network
activity
If these
mechanisms are correct, improvements may begin within hours or days rather than
months.
Long-term
studies remain essential
None of this
means that three-month or six-month follow-up should disappear.
Quite the
opposite.
The UCLA
study demonstrated that biological adaptation can reduce the effectiveness of
prolonged treatment.
Long-term
follow-up therefore remains essential for determining:
- durability of benefit
- development of tolerance
- adverse effects
- functional outcomes.
The point is
simply that early measurements and late measurements answer different
scientific questions.
Early
assessments tell us whether the drug is biologically active.
Later
assessments tell us whether the benefit persists.
Future
trials may therefore benefit from measuring both.
A typical
design might include:
- baseline
- 24–48 hours
- one week
- one month
- three months
- six months
Such studies
would distinguish:
- rapid responders,
- delayed responders,
- non-responders,
- and individuals who initially
improve but later develop tolerance.
The
Chinese sirolimus case: an example of an N-of-1 trial
One human
case illustrates both the promise and the limitations of this approach.
Chinese
physicians reported treating an 8-year-old boy with non-syndromic autism using
low-dose sirolimus (rapamycin).
The child
had previously received behavioural therapy together with aripiprazole but
remained significantly impaired.
He was then
prescribed sirolimus 1 mg daily, with blood concentrations maintained between 5
and 10 ng/mL.
Within
approximately two weeks, improvements in social interaction, eye contact,
hyperactivity and stereotypic behaviour were reported.
After
roughly two months he was attending a mainstream school successfully.
Treatment
reportedly continued for more than two years.
The
principal adverse effect consisted of recurrent mild-to-moderate mouth ulcers
(stomatitis), while routine blood tests remained largely normal during
specialist monitoring.
This report
is scientifically interesting.
It is not
scientifically conclusive. Other parents have tried to repeat this effect.
Nevertheless,
the report illustrates an important principle.
Clinicians
did not need to wait three months before recognising that something
biologically significant appeared to be happening.
The reported
improvement was already evident within two weeks.
The
subsequent months were important for determining whether the benefit persisted
and whether side effects emerged—not for detecting the initial response.
That
distinction is exactly the one highlighted by the UCLA study.
What can
we learn from N-of-1 medicine?
One of the
strengths of the autism community is its willingness to observe carefully.
Over the
years, many readers of Epiphany ASD have shared their experiences after
trialling therapies discussed on this blog under medical supervision.
Some
families have reported remarkable improvements.
Others have
seen no obvious benefit.
Some have
stopped treatment because of unacceptable side effects.
These
experiences cannot replace randomized controlled trials.
However,
they do remind us of an important fact.
Autism is
biologically heterogeneous.
A treatment
that transforms one child may do absolutely nothing for another.
Rather than
dismissing carefully documented individual experiences as "just
anecdotes," they can serve as valuable hypotheses that identify biological
subgroups deserving formal scientific investigation.
mTOR
Beyond the Brain – Why It Builds Muscle and Bone, Where Precision Medicine Is
Heading, and the Lasting Legacy of the UCLA Study
Up to this
point we have focused almost entirely on the brain.
However,
mTOR is not a "brain pathway."
It is one of
the body's master regulators of growth, repair and adaptation.
Understanding
this broader role helps explain both the promise and the limitations of
rapamycin as a potential autism therapy.
mTOR: one
pathway, many jobs
One reason
mTOR has attracted so much scientific attention is that it sits at the centre
of an enormous biological network.
It
integrates information about:
- nutrients
- energy availability
- growth factors
- hormones
- inflammation
- mechanical loading
before
deciding whether cells should:
- grow,
- divide,
- manufacture proteins,
- recycle damaged components
through autophagy,
- or conserve energy.
This makes
perfect evolutionary sense.
Growth is
expensive.
The body
should only build new tissue when sufficient energy and nutrients are
available.
The same
signalling pathway therefore helps regulate:
- brain development,
- immune function,
- muscle growth,
- bone formation,
- wound healing,
- ageing,
- metabolism.
That
explains why manipulating mTOR can have such widespread effects throughout the
body.
The figure
illustrates an important concept.
Although the
same signalling pathway is involved, its role differs dramatically depending on
the tissue.
In the
brain
Pathological
activation may produce:
- neuronal hyperexcitability
- abnormal sensory processing
- disrupted functional brain
networks
- repetitive behaviours
- increased seizure susceptibility
The goal is normalization.
In muscle
Physiological
activation stimulates:
- muscle protein synthesis
- repair following exercise
- adaptation to resistance
training
- increased strength
The goal is preservation.
In bone
Mechanical
loading activates mTOR within osteoblasts, stimulating:
- bone formation
- collagen synthesis
- skeletal adaptation
- increased bone strength
Again, the
goal is preservation, not inhibition.
Why
exercise activates mTOR—and why that is a good thing
Readers of Epiphany
ASD know that I frequently discuss the benefits of exercise.
At first
glance, this might appear contradictory.
If excessive
mTOR activity can contribute to autism, why encourage activities that activate
mTOR?
The answer
lies in one of the most important concepts in physiology.
It is
essential to distinguish between:
physiological mTOR activation
and
pathological mTOR dysregulation.
When we
perform resistance exercise, climb a steep hill carrying a backpack or lift
weights, mTOR activation is:
- temporary,
- tightly regulated,
- largely confined to the muscles
and bones being exercised.
This is
exactly what we want.
It allows
the body to adapt to increased mechanical loading by becoming stronger.
Similarly,
consuming high-quality protein—particularly protein rich in the amino acid leucine—temporarily
activates mTOR within skeletal muscle, stimulating muscle protein synthesis and
recovery after exercise.
These are
normal physiological responses.
The autism
models discussed earlier are fundamentally different.
They
involve:
- chronic dysregulation
- abnormal signalling
- specific neuronal populations
- altered brain circuit function
These are
not equivalent biological states.
Healthy
activation of mTOR after exercise should not be confused with pathological
overactivation within particular brain circuits.
Leucine:
a natural activator of mTOR
Leucine
deserves particular mention because it illustrates how precisely the body
regulates mTOR.
Leucine is
one of the three branched-chain amino acids and is a powerful nutritional
signal that activates mTORC1.
After a
protein-rich meal—particularly one containing dairy products or whey
protein—blood leucine concentrations rise.
Muscle cells
interpret this as evidence that sufficient amino acids are available to build
new proteins.
The result
is increased muscle protein synthesis.
This
explains why resistance exercise combined with adequate dietary protein is so
effective for maintaining muscle mass during ageing.
It also
illustrates an important point.
Simply
activating mTOR is neither inherently good nor inherently bad.
Everything
depends on:
- which tissue
- which cells
- how long
- and how much
The body
uses exactly the same signalling pathway for healthy adaptation and for
disease.
Context is
everything.
Why
chronic rapamycin has drawbacks
Unfortunately,
rapamycin cannot distinguish between tissues.
It inhibits
mTOR wherever it reaches sufficient concentrations.
That creates
an obvious problem.
While
reducing excessive mTOR activity in overactive neuronal circuits may be
beneficial, suppressing normal mTOR activity elsewhere in the body may produce
unwanted effects.
Long-term
treatment can potentially reduce:
- muscle protein synthesis
- exercise adaptation
- bone formation
- wound healing
- immune function
These
considerations are particularly important in children and adolescents, whose
brains, muscles and skeletons are still developing.
This is
another reason why rapamycin itself is unlikely to become a universal autism
treatment.
The
challenge is to normalize abnormal brain signalling without interfering with
the many beneficial roles of mTOR elsewhere in the body.
The
future lies in selective regulation
Ideally,
future therapies will behave much more like thermostats than on-off switches.
Instead of
suppressing mTOR throughout the entire body, they would:
- reduce excessive signalling
where it is pathological,
- preserve normal signalling where
it is physiological,
- restore deficient signalling
where it is inadequate.
Achieving
that level of precision remains a major scientific challenge.
However,
many areas of medicine are already moving in exactly this direction.
Cancer
therapy has evolved from broadly toxic chemotherapy towards molecularly
targeted treatments.
Immunology
has progressed from general immunosuppression to selective biological
therapies.
Autism may
eventually undergo a similar transformation.
Precision
medicine will probably use combinations, not miracle drugs
One of the
recurring themes throughout this article has been convergence.
Different
biological abnormalities often disturb the same neuronal circuits.
Likewise,
different therapies often move those circuits back towards normal through
different mechanisms.
Future
treatment may therefore consist of carefully selected combinations of
relatively modest interventions.
For example:
- a statin reducing excessive Ras
signalling;
- metformin moderating mTOR
activity through AMPK;
- bumetanide restoring GABAergic
inhibition;
- a calcium channel blocker
correcting abnormal calcium influx;
- behavioural interventions
strengthening newly balanced circuits.
Each
intervention may contribute only part of the solution.
Together
they may restore healthier neuronal physiology.
This
approach resembles the management of hypertension, diabetes and heart failure,
where combination therapy has become routine because complex biological systems
rarely respond optimally to a single intervention.
Conclusions
Fifteen
years ago researchers believed rapamycin might become a treatment for tuberous
sclerosis.
Today, the
UCLA study suggests something far more important.
Rapamycin
has shown us that adult autistic brain circuits remain remarkably plastic.
Its greatest
contribution may therefore not be as a medicine.
It may be as
the experimental tool that demonstrated a new principle of autism biology.
The future
is unlikely to belong to rapamycin itself.
Instead, it
belongs to precision medicine.
Rather than
treating "autism" as a single disorder, clinicians will increasingly
identify the disrupted biological pathway in each individual and select
therapies designed to restore that pathway to its normal physiological range.
Some
individuals may require reduced mTOR signalling.
Others may
require increased trophic support.
Still others
may benefit from correcting calcium signalling, chloride transport,
mitochondrial function or neuroinflammation.
The
diagnosis may remain the same.
The biology
will not.
Perhaps that
is the greatest lesson of the UCLA study.
It reminds
us that the question is no longer:
"Can
we rebuild the autistic brain?"
Instead, we
can begin asking:
"Can
we restore healthier function to autistic brain circuits?"
For the
first time, that question appears scientifically realistic.
